The optimal antiviral regimen for hepatitis C virus (HCV) genotype 4 is still a subject of investigation. The report in this issue of Health Science Reports by Asselah and colleagues investigated the additional benefit of extending treatment duration of the ombitasvir/paritaprevir/ritonavir plus ribavirin regimen to up to 24 weeks for patients with HCV genotype 4 and compensated cirrhosis.
The optimal antiviral regimen for hepatitis C virus (HCV) genotype 4 is still a subject of investigation. The report in this issue of Health Science Reports by Asselah and colleagues investigated the additional benefit of extending treatment duration of the ombitasvir/paritaprevir/ritonavir plus ribavirin regimen to up to 24 weeks for patients with HCV genotype 4 and compensated cirrhosis.
HCV genotype 4 accounts for over 8% of all patients with HCV infection globally. This genotype is predominantly found in patients from Egypt. Its prevalence varies widely by regions, with the highest prevalence reported in the Middle East and sub-Saharan Africa. 1 The geographic distribution of patients with HCV genotype 4 infection is increasing, however, due to migration. In addition, longer treatment duration did not offer additional benefit on short-term regression of liver fibrosis. These negative results are important for establishing the optimal regimen for patients with HCV genotype 4.
There is substantial genetic heterogeneity in HCV genotype 4, and many subgenotypes have been reported, although, with the exception of subtypes 4a and 4b, the prevalence of these subtypes is low. The efficacy of DAA regimens by subgenotype is unclear and will be the subject of further research. Although some trials that focused on patients with HCV genotype 4 have included more than 100 patients, 6,7 most patients had HCV subgenotype 4a or 4d. The most recent study by Fourati et al 8 reported an unexpectedly high rate of treatment failure in patients with HCV subgenotype 4r, a genotype which has been reported in African countries but that is rarely found in regions such as Europe and North America, which is associated with a high frequency of baseline resistance-associated substitutions.
Based on their report, it could be proposed that subgenotype evaluation should be recommended in patients with HCV genotype 4 when selecting a treatment regimen. However, given the low proportion of 4r in the overall HCV-infected population and the lack of available commercial assays to identify HCV genotype 4 subtypes, 9 universal subtyping of all genotype 4-infected patients to select regimen may be difficult to implement in actual clinical practice at this time.
The ideal DAA regimen for HCV genotype 4 has not been fully 
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